Skip to content

Resuscitation Quick Actions • First 2 Minutes

High-Acuity

Acute Dystonia Antidote

Diphenhydramine 50 mg IV/IM OR Benztropine 1 to 2 mg IV/IM; rapid symptom reversal within 5 to 15 minutes

Discharge Prescription Rule

Prescribe oral Benztropine 1–2 mg PO BID (or Diphenhydramine 25–50 mg PO TID) for 3–5 days to prevent secondary rebound dystonia

Akathisia Treatment

Propranolol 10 to 20 mg PO BID (or Lorazepam 1 mg PO/IV); motor restlessness is routinely misdiagnosed as worsening psychosis!

NMS Clinical Tetrad

1) Hyperthermia (> 38–40°C), 2) 'Lead-pipe' muscle rigidity, 3) Autonomic instability (labile BP, tachycardia), 4) Altered mental status

NMS vs Serotonin Syndrome

NMS: 'Lead-pipe' rigidity, hyporeflexia, slow onset (days); Serotonin Syndrome: Tremor, HYPERREFLEXIA, CLONUS, hyperacute onset (hours)

NMS Pharmacotherapy

Bromocriptine 2.5–5 mg PO/NG q8h (dopamine agonist) + Dantrolene 1–2.5 mg/kg IV push (ryanodine receptor blocker) for severe rigidity

Bottom-Line Clinical Pearl

Acute dystonic reactions occur within 24 to 72 hours of starting or increasing dopamine D2 receptor antagonists (first-generation antipsychotics [haloperidol, fluphenazine] or antiemetics [metoclopramide, prochlorperazine]). It manifests as sustained, involuntary, painful muscle contractions: torticollis (neck twisting), trismus (jaw clenching), oculogyric crisis (involuntary upward eye deviation), or life-threatening laryngeal dystonia. Treatment is immediate IV Diphenhydramine (50 mg IV) or IV Benztropine (1–2 mg IV); symptoms resolve dramatically within 5–15 minutes. Always discharge the patient on a 3- to 5-day course of oral benztropine (1–2 mg PO BID) or diphenhydramine to prevent severe rebound dystonia. Distinguish NMS (lead-pipe rigidity, bradyreflexia, slow onset over days) from Serotonin Syndrome (spontaneous clonus, hyperreflexia, hyperactive bowel sounds, hyperacute onset over hours).

1. Pathophysiology: Striatal Dopamine-Acetylcholine Balance

In the basal ganglia (caudate, putamen, substantia nigra), smooth voluntary motor control requires an intricate equilibrium between inhibitory dopaminergic signaling (D2 receptors) and excitatory cholinergic signaling (muscarinic acetylcholine receptors). High-potency dopamine receptor antagonists (antipsychotics: haloperidol, fluphenazine; and antiemetics: metoclopramide, prochlorperazine) abruptly block striatal D2 receptors, creating unchecked relative cholinergic overactivation, precipitating acute involuntary muscular contractions and dystonic spasms.

Movement DisorderOnset Post-ExposureClinical Hallmarks & PresentationEmergency Treatment Regimen
Acute Dystonic ReactionHours to 3 daysPainful involuntary muscle spasms: Torticollis (spasmodic neck twisting), Oculogyric crisis (fixed, locked upward gaze deviation), Trismus (inability to open jaw), Opisthotonos (severe backward spinal arching), and Laryngeal dystonia (stridor/airway obstruction)Diphenhydramine 50 mg IV/IM OR Benztropine 1 to 2 mg IV/IM. Symptoms resolve within 5–15 minutes. Prescribe oral maintenance therapy for 3 to 5 days to prevent rebound.
AkathisiaDays to weeksIntense, agonizing subjective feeling of inner restlessness with uncontrollable urge to move: pacing, shifting weight, rocking back and forth, crossing/uncrossing legs. Frequently misdiagnosed as worsening psychotic agitation, leading to inappropriate antipsychotic dose escalation!Propranolol 10 to 20 mg PO BID (first-line) OR Lorazepam 0.5–1.0 mg PO/IV; discontinue or lower dose of offending antipsychotic.
Drug-Induced ParkinsonismWeeks to monthsTriad of bradykinesia/akinesia, resting 'pill-rolling' tremor, and cogwheel rigidity; masked facies, shuffling gaitOral anticholinergics (Benztropine 1–2 mg daily); switch to an atypical second-generation antipsychotic with low D2 affinity (e.g., quetiapine).
Tardive DyskinesiaMonths to years (Late)Involuntary, repetitive, choreoathetoid movements of face, mouth, tongue (lip smacking, tongue protrusion/'fly-catcher tongue', grimacing, chewing movements); may be irreversibleDiscontinue offending agent; Valbenazine or Deutetrabenazine (VMAT2 inhibitors). Anticholinergics worsen tardive dyskinesia!

2. Neuroleptic Malignant Syndrome (NMS) vs. Serotonin Syndrome

Diagnostic DomainNeuroleptic Malignant Syndrome (NMS)Serotonin Syndrome (SS)
Causative XenobioticsDopamine D2 antagonists (Haloperidol, Fluphenazine, Metoclopramide) or abrupt withdrawal of dopamine agonists (Levodopa)Pro-serotonergic combinations (SSRIs, SNRIs, MAOIs, TCAs, Tramadol, Linezolid, Fentanyl, MDMA)
Speed of OnsetSlow and insidious over 1 to 3 days (or weeks)Hyperacute onset over hours (< 24 hours)
Neuromuscular Tone'Lead-pipe' generalized rigidity; resistance throughout passive motion; cogwheelingTremor, Marked Hyperreflexia, and Spontaneous or Inducible CLONUS (ocular clonus, ankle clonus)
Pupils & Bowel SoundsNormal pupils; normal or decreased bowel soundsMydriasis (dilated pupils); Hyperactive, borborygmic bowel sounds with diarrhea
Laboratory HallmarksMassive Creatine Kinase (CK) elevation (> 1,000 to 50,000+ U/L), leukocytosis (15–30k), metabolic acidosisMild CK elevation; metabolic acidosis in severe hyperthermia
Specific AntidotesBromocriptine (dopamine agonist) + Dantrolene (ryanodine receptor calcium release blocker)Cyproheptadine (12 mg PO/NG load, then 2 mg q2h; potent 5-HT2A antagonist)
Board & Shelf Drill 5 Questions • Untimed Tutor Mode

Test Your Acute Movement Disorders, Dystonias & Drug Reactions Clinical Acumen

Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.